With respect to the MOAs of olverembatinib in this type of rare cancer, first, biomarker analysis using tumor samples from patients in the current clinical trial offered clues that better clinical efficacy of olverembatinib is associated with upregulated lipid metabolism in SDH-deficient GIST patients. The gene discussed is SDHB; the disease is cancer.